Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks immune cell function after stem cell transplants to personalize care

NCT ID NCT04635397

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could help predict and manage complications like infections, relapse, and graft-versus-host disease (GvHD).

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors personalize post-transplant care by adjusting immune-suppressing drugs or anti-infection treatments based on a patient's immune recovery.
What could go wrong
This is an observational study, not a treatment trial. It aims to gather information, not test a new therapy, so it won't directly improve outcomes for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

61 people

The number who actually took part.

Started

Feb 2021

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients receiving an allogeneic stem cell transplantation for an hematological malignancy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years old * Suffering from a malignant hemopathy * Allogeneic bone marrow or hematopoietic stem cells * Identical geno-, pheno- and haplo donors * Informed consent signed by the patient or the person of trust in case of impossibility (deferred consent of the patient when his condition allows it) * Affiliated with a social security scheme Exclusion Criteria: * Patient with a clinical or biological contraindication to performing an allogeneic transplant * Patient with progressive solid cancer or in remission for less than 3 years * HIV-positive patients * Patients with chronic active hepatitis B or C * Allogeneic cord blood transplant * Allograft with sequential conditioning * Post-allograft preemptive treatment other than injections of donor lymphocytes Withdrawal of informed consent * Inability to undergo medical monitoring of the study for geographical, social or psychological reasons Non-inclusion criteria: * Minor patient * Pregnant woman * Patient with congenital or previously acquired immune deficiency * Patient on prior immunosuppressive treatment * Patient under guardianship or guardianship or placed in detention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute leukemias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute leukemia hematopoietic and lymphoid cell neoplasm myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic stem cell transplantation

Contacts and locations

Locations

  • CHU de Nice

    Nice, CHU de NICE, 06003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.